Cancer Research UK-MedImmune Alliance Laboratory (CMAL)

CRUK-MEDI Alliance Laboratory

Novel, collaborative antibody discovery to accelerate delivery of therapies and diagnostics for cancer patients 

Our laboratory brings together Cancer Research UK’s cancer biology expertise with the world-class antibody engineering technology of MedImmune, the global biologics research and development arm of AstraZeneca, to accelerate antibody discovery. 

Scientists from both organisations work side by side in the joint laboratory in Granta Park, Cambridge. Utilising MedImmune’s phage display libraries, we share knowledge and expertise to discover and develop novel biologics to treat and diagnose cancer.  

How you can work with us

Are you an academic scientist working in cancer, immunology or autoimmunity research?

We’re keen for you to come forward with molecular targets for antibody discovery, based on novel biological insights, and we welcome applications all year round.

Your proposed therapeutic targets must be extracellular; either a soluble protein or an integral membrane protein exposed on the surface of a cell. Direct tumour cell targets should be upregulated in, or unique to, cancer cells.

Our collaborative model

We’ll provide you with the opportunity to be an integral member of the project team. In addition, you can:

  • Translate your idea into a drug to help deliver patient benefit
  • Secure resources and funding to conduct research on your target
  • Be a key member of a multidisciplinary drug discovery team
  • Access leading biotherapeutic drug discovery technologies
  • Author research articles and patents.

CMAL can help you fulfil your ambition to make an outstanding contribution to cancer research and ultimately help produce a therapy which could transform patients’ lives.

Professor Martin GlennieCMAL provides a route for academic investigators to access world-class antibody drug discovery capabilities. The lab staff have established strong collaborative relationships with leading UK investigators and worked quickly and efficiently to generate antibody-based tools and potential therapeutics.  

– Professor Martin Glennie, University of Southampton

Contact us

To find out more about collaborating with CMAL, contact:

Julie Little

Business Development Executive

Julie.little@cancer.org.uk

+44 (0) 203 469 6718

Meet the team

Members of the CMAL team will be at the following events:

CMAL and Therapeutic Discovery Laboratories joint seminar, Edinburgh, UK
5 July 2018

CMAL and MedImmune joint seminar, ICR, London, UK
2 August 2018

Email us for more information or to arrange a meeting at one of these events.

Contact us

To hear more about CMAL and the opportunities this collaboration offers you, get in touch with Julie Little on julie.little@cancer.org.uk or via phone on +44(0)2034696718.

 

 

Where next for cancer immunotherapy?

Where next for cancer immunotherapy?

We're driving discovery research in immuno-oncology which is leading to novel and exciting immunotherapeutic possibilities.

Celebrating Cancer Research UK-MedImmune Alliance Laboratory

Celebrating UK Bioscience - Cancer case study

As part of a series celebrating UK expertise in drug discovery and development, the UK BioIndustry Association visited the CRUK-MedImmune Alliance Laboratory.

Share this page